文献速递白血病

接受维奈克拉联合低甲基化药物治疗的难治/复发性急性髓系白血病患者的新型预后风险模型

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
PubMed 文献 · Leukemia · 2025-01-08

这项回顾性观察性多中心研究纳入240例接受超说明书低甲基化药物联合维奈克拉(HMA/VEN)治疗的难治/复发性急性髓系白血病成人患者,中位年龄68.6岁,总缓解106例(44%),中位随访31.5个月记录179例死亡,中位总生存7.9个月。基于174例有分子信息患者的多元分析构建HR加权三风险组模型,并在189例一线HMA/VEN治疗患者中验证。

要点

  • 总缓解106例(44%),中位随访31.5个月,179例死亡,中位总生存7.9个月。
  • 不良预后因素包括髓外病变、HMA预处理及NF1、PTPN11、FLT3、TP53突变,SF3B1突变为有利因素。
  • 风险模型分三组:预后良好组46例中位总生存21.4个月,中间组75例7.5个月,不良组53例4.6个月(p<0.001)。

核心结论

  • 该临床-分子三层次维奈克拉预后风险评分(VEN-PRS)可用于预测接受HMA/VEN治疗的难治/复发性急性髓系白血病患者的治疗结局,并支持在该高危人群中选择合适的治疗方案。

研究设计与样本

  • 回顾性观察性多中心研究,纳入240例接受超说明书HMA/VEN治疗的难治/复发性急性髓系白血病成人患者,中位年龄68.6岁。
  • 在174例有分子信息的患者亚组中进行多元分析筛选预后因素,构建HR加权风险模型,并在189例一线接受HMA/VEN治疗的急性髓系白血病患者中验证。

主要发现

  • 总缓解106例(44%);中位随访31.5个月,记录179例死亡;中位总生存7.9个月。
  • 多元分析显示不良生存风险因素包括髓外病变、HMA预处理及NF1、PTPN11、FLT3、TP53突变,SF3B1突变为有利风险因素。
  • 风险模型将患者分为三组:预后良好组46例中位总生存21.4个月,中间组75例7.5个月,不良组53例4.6个月(p<0.001)。

关键数值与推荐

  • 总缓解106例(44%),中位随访31.5个月,179例死亡,中位总生存7.9个月。
  • 预后良好组46例中位总生存21.4个月,中间组75例7.5个月,不良组53例4.6个月(p<0.001)。
  • 不良预后因素:髓外病变、HMA预处理及NF1、PTPN11、FLT3、TP53突变;有利因素:SF3B1突变。

临床怎么用

  • 作者认为,该VEN-PRS风险评分可支持在接受HMA/VEN治疗的难治/复发性急性髓系白血病高危人群中选择合适的治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded. Median overall survival (mOS) was 7.9 months. In multivariate analysis of the subgroup with molecular information (n = 174), risk factors for inferior survival included the presence of extramedullary disease, HMA pretreatment and mutations in NF1, PTPN11, FLT3, and TP53, whereas mutated SF3B1 was identified as favorable risk factor. These risk factors were subsequently applied to construct an HR-weighted risk model that allocated patients to one of three risk groups with significantly different survival outcomes: favorable (n = 46; mOS 21.4 months), intermediate (n = 75; mOS 7.5 months), and adverse (n = 53; mOS 4.6 months; p < 0.001). The model was validated in 189 AML patients treated with HMA/VEN in first line. This clinical-molecular, 3-tiered venetoclax prognostic risk score (VEN-PRS) for HMA/VEN treatment outcomes in R/R AML patients will support the selection of appropriate treatment options in this high-risk population.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shahswar R, Gabdoulline R, Krueger K, et al. A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025. PMID: 39779979. doi:10.1038/s41375-024-02501-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。